The Outlook for the HR+/HER2- MBC Treatment Landscape in 2025 and Beyond Live Webinar will focus on the latest advancements and future directions in treating HR+ HER2- metastatic breast cancer (MBC). Experts will review recent clinical trial data, discuss the current treatment landscape, and explore the role of novel therapies, including CDK4/6 inhibitors, PI3K inhibitors, and targeted therapies. The evolving landscape will also include next-generation treatments that could reshape patient care in the coming years.
Biomarker testing plays a central role in guiding treatment decisions for HR+ HER2- MBC, and the conference will cover how genomic tests and liquid biopsies, such as ctDNA, can help personalize therapies. A discussion will also take place on the balance between biomarker-driven therapies versus non-biomarker approaches, addressing when and how each strategy should be utilized in clinical practice.
The conference will also focus on optimizing treatment sequencing based on clinical characteristics such as tumor burden, mutational status, and patient performance. Esteemed speakers include Dr. Martin Miguel (Hospital General Universitario Gregorio Marañón, Spain), Dr. Neven Patrick (Universitaire Ziekenhuizen Leuven, Belgium), and Dr. Joyce O’Shaughnessy (Baylor-Sammons Cancer Center, USA), who will share their expertise on the latest research and treatment strategies for HR+ HER2- MBC.
